Illumina’s board began looking for potential CEO replacements approximately two months before the resignation of then-leader Francis deSouza, during an intense proxy campaign targeting the
The FDA on Tuesday tentatively approved a pediatric version of an HIV-1 treatment following a successful public-private partnership between the Clinton Health Access Initiative, Unitaid,
An appeals court on Friday revived a lawsuit that several doctors filed against the FDA last year, alleging that the agency overstepped its authority in
Peanut allergies proved a tough nut to crack for Nestlé, which announced Monday it has divested its treatment Palforzia to Swiss allergy specialist Stallergenes Greer.
The University of Illinois Chicago’s College of Pharmacy last week petitioned the FDA to remove clinical efficacy testing for all new biosimilars — and not
Novartis is the latest drugmaker to sue the federal government over the Inflation Reduction Act after learning its blockbuster heart drug Entresto will be up
The groups are called the MET Crusaders, the EGFR Resistors, the KRAS Kickers and the ROS1ders — and members are non small cell lung cancer
MacroGenics is set to receive a $15 million milestone payment from Gilead, which is using the company’s two bispecific antibody platforms in a research program.
BioCardia disclosed that its heart failure stem cell therapy failed to hit on all three measures that comprised the primary endpoint of a Phase III
Olema Oncology, the Bay Area biotech run by former AstraZeneca executive Sean Bohen, raised $130 million from a private placement and a credit facility of